Literature DB >> 23624751

Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ.

Laura C Collins1, Ninah Achacoso, Reina Haque, Larissa Nekhlyudov, Suzanne W Fletcher, Charles P Quesenberry, Stuart J Schnitt, Laurel A Habel.   

Abstract

We aimed to identify clinicopathologic factors associated with local recurrence (LR) in a large population of DCIS patients treated with breast-conserving therapy between 1990-2001 in three health plans. Regression methods were used to estimate relative risks (RR) of LR. Among 2,995 patients, 325 had a LR [10.9 %; median follow-up 4.8 years (range 0.5-15.7)]. After adjusting for health plan and treatment, risk of LR was increased among women <45 years (RR = 2.1, 95 % CI 1.5-2.8), African-Americans (RR = 1.6; 95 % CI 1.1-2.1) and those with DCIS detected because of signs/symptoms (RR = 1.6; 95 % CI 1.2-2.0). After also adjusting for age and diagnosis year, pathologic features associated with increased LR were larger lesion size (RR = 2.9 for ≥20 low power fields of DCIS; 95 % CI 1.6-5.6) and involved (RR = 2.9; 95 % CI 1.6-5.2), or close margins (RR = 2.4; 95 % CI 1.6-3.8). Presentation with symptoms/signs was associated with increased risk of invasive recurrence; while African-American race, larger tumor size, and involved/close tumor margins were more strongly associated with increased risk of DCIS recurrence. Our findings suggest some risk factors differ for non-invasive and invasive LRs and that most factors are only moderately associated with increased LR risk. Future research efforts should focus on non-clinicopathologic factors to identify more powerful risk factors for LR.

Entities:  

Mesh:

Year:  2013        PMID: 23624751      PMCID: PMC4104603          DOI: 10.1007/s10549-013-2539-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  32 in total

1.  Young age is not associated with increased local recurrence for DCIS treated by breast-conserving surgery and radiation.

Authors:  Aruna Turaka; Gary M Freedman; Tianyu Li; Penny R Anderson; Ramona Swaby; Nicos Nicolaou; Lori Goldstein; Elin R Sigurdson; Richard J Bleicher
Journal:  J Surg Oncol       Date:  2009-07-01       Impact factor: 3.454

2.  Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast.

Authors:  M J Silverstein; A Barth; D N Poller; E D Gierson; W J Colburn; J R Waisman; P Gamagami
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

3.  Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Authors:  Karla Kerlikowske; Annette M Molinaro; Mona L Gauthier; Hal K Berman; Fred Waldman; James Bennington; Henry Sanchez; Cynthia Jimenez; Kim Stewart; Karen Chew; Britt-Marie Ljung; Thea D Tlsty
Journal:  J Natl Cancer Inst       Date:  2010-04-28       Impact factor: 13.506

4.  Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans.

Authors:  Reina Haque; Ninah S Achacoso; Suzanne W Fletcher; Larissa Nekhlyudov; Laura C Collins; Stuart J Schnitt; Charles P Quesenberry; Laurel A Habel
Journal:  Am J Manag Care       Date:  2010-05       Impact factor: 2.229

5.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

Authors:  B Fisher; J Dignam; N Wolmark; D L Wickerham; E R Fisher; E Mamounas; R Smith; M Begovic; N V Dimitrov; R G Margolese; C G Kardinal; M T Kavanah; L Fehrenbacher; R H Oishi
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

Review 6.  Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics.

Authors:  Stuart J Schnitt
Journal:  J Natl Cancer Inst Monogr       Date:  2010

7.  Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients.

Authors:  Laura C Collins; Ninah Achacoso; Larissa Nekhlyudov; Suzanne W Fletcher; Reina Haque; Charles P Quesenberry; Balaram Puligandla; Najeeb S Alshak; Lynn C Goldstein; Allen M Gown; Stuart J Schnitt; Laurel A Habel
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

8.  Ductal carcinoma in situ in African American versus Caucasian American women: analysis of clinicopathologic features and outcome.

Authors:  Hind Nassar; Bashar Sharafaldeen; Kala Visvanathan; Daniel Visscher
Journal:  Cancer       Date:  2009-07-15       Impact factor: 6.860

9.  Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy.

Authors:  Karla Kerlikowske; Annette Molinaro; Imok Cha; Britt-Marie Ljung; Virginia L Ernster; Kim Stewart; Karen Chew; Dan H Moore; Fred Waldman
Journal:  J Natl Cancer Inst       Date:  2003-11-19       Impact factor: 13.506

10.  Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting.

Authors:  Laurel A Habel; Ninah S Achacoso; Reina Haque; Larissa Nekhlyudov; Suzanne W Fletcher; Stuart J Schnitt; Laura C Collins; Ann M Geiger; Balaram Puligandla; Luana Acton; Charles P Quesenberry
Journal:  Breast Cancer Res       Date:  2009-11-18       Impact factor: 6.466

View more
  16 in total

1.  Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ.

Authors:  Megan E Miller; Shirin Muhsen; Emily C Zabor; Jessica Flynn; Cristina Olcese; Dilip Giri; Kimberly J Van Zee; Melissa Pilewskie
Journal:  Ann Surg Oncol       Date:  2019-09-24       Impact factor: 5.344

2.  Racial disparities in risk of second breast tumors after ductal carcinoma in situ.

Authors:  Ying Liu; Graham A Colditz; Sarah Gehlert; Melody Goodman
Journal:  Breast Cancer Res Treat       Date:  2014-09-27       Impact factor: 4.872

3.  Comparing treatment and outcomes of ductal carcinoma in situ among women in Missouri by race.

Authors:  Chinwe C Madubata; Ying Liu; Melody S Goodman; Shumei Yun; Jennifer Yu; Min Lian; Graham A Colditz
Journal:  Breast Cancer Res Treat       Date:  2016-10-22       Impact factor: 4.872

4.  Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years.

Authors:  Preeti Subhedar; Cristina Olcese; Sujata Patil; Monica Morrow; Kimberly J Van Zee
Journal:  Ann Surg Oncol       Date:  2015-07-28       Impact factor: 5.344

5.  A comparison of the risks of in-breast recurrence after a diagnosis of dcis or early invasive breast cancer.

Authors:  S A Narod; E Rakovitch
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

6.  Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community.

Authors:  Michael J Hassett; Wei Jiang; Laurel A Habel; Larissa Nekhlyudov; Ninah Achacoso; Luana Acton; Stuart J Schnitt; Deb Schrag; Rinaa S Punglia
Journal:  Breast Cancer Res Treat       Date:  2016-02-03       Impact factor: 4.872

Review 7.  Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.

Authors:  Kevin Shee; Kristen E Muller; Jonathan Marotti; Todd W Miller; Wendy A Wells; Gregory J Tsongalis
Journal:  Am J Pathol       Date:  2018-10-29       Impact factor: 4.307

Review 8.  Current view on ductal carcinoma in situ and importance of the margin thresholds: A review.

Authors:  A Van Cleef; S Altintas; M Huizing; K Papadimitriou; P Van Dam; W Tjalma
Journal:  Facts Views Vis Obgyn       Date:  2014

9.  Predictors for local invasive recurrence of ductal carcinoma in situ of the breast: a meta-analysis.

Authors:  Xining Zhang; Hongji Dai; Ben Liu; Fengju Song; Kexin Chen
Journal:  Eur J Cancer Prev       Date:  2016-01       Impact factor: 2.497

10.  Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.

Authors:  Lotte E Elshof; Michael Schaapveld; Marjanka K Schmidt; Emiel J Rutgers; Flora E van Leeuwen; Jelle Wesseling
Journal:  Breast Cancer Res Treat       Date:  2016-09-08       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.